|
|
|
|
|
|
Sponsored by: |
Genentech |
Information provided by: | Genentech |
ClinicalTrials.gov Identifier: | NCT00109317 |
This is a Phase IIIb, randomized, double-blind, parallel-group, placebo-controlled, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with moderate to severe plaque psoriasis who are candidates for systemic therapy.
Condition | Intervention | Phase |
Psoriasis |
Drug: Raptiva (efalizumab) |
Phase III |
MedlinePlus related topics: | Psoriasis |
ChemIDplus related topics: | Efalizumab |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety Study |
Official Title: | A Phase IIIb, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety of 1.0 Mg/Kg Subcutaneously Administered Efalizumab in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Results 
  |
Study ID Numbers: | ACD2600g |
First Received: | April 27, 2005 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00109317 |
Health Authority: | United States: Food and Drug Administration |
|
|